Growth Hormone Peptides (Secretagogues)

Growth-hormone-releasing peptides and secretagogues stimulate the body’s own GH release rather than supplying synthetic hormone. They differ in potency, half-life, GH-pulse shape and side-effect profile — from the selective ipamorelin to the long-acting CJC-1295 and the appetite-driving GHRP-6. Here is the full class, compared and referenced.

Profiles

• AOD9604 (HGH fragment 176-191): Mechanism, Benefits & Research Evidence
• CJC-1295 with DAC (drug affinity complex, albumin-binding): Mechanism, Benefits & Research Evidence
• CJC-1295 without DAC (Modified GRF 1-29 / Mod-GRF): Mechanism, Benefits & Research Evidence
• GHRP-2 Acetate: Mechanism, Benefits & Research Evidence
• GHRP-6 Acetate: Mechanism, Benefits & Research Evidence
• HGH (recombinant human growth hormone, somatropin): Mechanism, Benefits & Research Evidence
• Hexarelin Acetate: Mechanism, Benefits & Research Evidence
• IGF-1 LR3 (Long-R3 IGF-1): Mechanism, Benefits & Research Evidence
• IGF-DES (Des(1-3)-IGF-1): Mechanism, Benefits & Research Evidence
• Ipamorelin: Mechanism, Benefits & Research Evidence
• MGF (Mechano Growth Factor, IGF-1Ec splice variant): Mechanism, Benefits & Research Evidence
• Sermorelin Acetate: Mechanism, Benefits & Research Evidence
• Tesamorelin: Mechanism, Benefits & Research Evidence

Comparisons

• CJC-1295 without DAC (Modified GRF 1-29 / Mod-GRF) vs Ipamorelin: A Comparative Analysis
• GHRP-2 Acetate vs GHRP-6 Acetate: A Comparative Analysis
• Ipamorelin vs Sermorelin Acetate: A Comparative Analysis of Two GH-Releasing Peptides

Questions & Evidence

• If Tesamorelin produces less IGF-1 elevation than equivalent GH-induced fat loss would predict, what alternative pathway (lipolysis-direct, central) is doing the work — and does that mean GH-axis side-effect concerns are overstated?